K. M. Hvizdos, K. Goa, J. Noord
2002
Citations
0
Influential Citations
29
Citations
Quality indicators
Journal
Drugs
Abstract
A Tiotropium bromide is an anticholinergic bronchodilator that antagonises muscarinic M 1 , M 2 and M 3 3 receptors. It dissociates more slowly from M 1 receptors and, importantly, from M 3 receptors (which are located in bronchial smooth muscle) than from M 2 receptors and subsequently has a long duration of action permitting once-daily administration. A In patients with chronic obstructive pulmonary disease (COPD), tiotropium 18μg once daily significantly improved lung function compared with placebo and ipratropium 40μg four times daily in 1-year trials or salmeterol 50μg twice daily in a 6-month study. A The incidence of COPD exacerbations decreased and use of rescue medication was lower with tiotropium compared with placebo or ipratropium. There was no evidence of tachyphylaxis during 1-year treatment with tiotropium. A Compared with placebo, salmeterol and ipratropium, tiotropium produced significant improvements in patients' perception of dyspnoea and health-related quality of life. A Tiotropium is generally well tolerated; dry mouth is the most common drug-related adverse event, occurring in about 10 to 16% of patients in clinical trials.